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beta-1b (interferons) and natalizumab and the reactions suspected of being asso-
ciated with them were identified. Disproportionality analyses used the Multi-item
Poisson Gamma Shrinker method with WHO-ART diagnosis at the preferred term
level for all AEs and for the standard combination of all WHO =critical terms=.
Statistical significance for disproportionality was defined as an Empirical Bayesian
Geometric Mean lower fifth percentile (EBGM05) 2.0. Comparisons were made
between GA versus all other drugs and GA versus interferons and natalizumab.
Sales data for GA were available to calculate reporting rates. RESULTS: A total of
2,320 cases with 6,680 AEs with a suspected relationship with GA and 20,155 cases
with 72,326 AEs for interferons and natalizumab were identified. Compared with all
other drugs in Vigibase and with interferons and natalizumab, GA was associated
with several statistically significant observations of disproportionate reporting.
WHO =critical terms= combined were not higher for GA versus interferons and
natalizumab (EBGM of 0.84 (90% credibility interval 0.79-0.90). The reporting rate of
WHO =critical terms= for GA was 69 events/100,000 person-year. CONCLUSIONS: In
a risk-benefit analysis of GA based on traditional meta-analysis, the number of AEs
in eligible controlled placebo/untreated and head-to-head studies were limited. In
such a situation analysis of a global large spontaneous AEs database permitted the
assessment of non-common and important risks. However, the biases inherent in
these databases need to be addressed.
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OBJECTIVES:Ambulation is the most highly valued bodily function for MS patients
(Heesen et al.), with ambulation problems recorded in up to 75% of patients (Hobart
et al.). Fampridine is a first-in-class treatment for ambulation. It improves the
conductivity of the nerves where demyelination has occurred. A preliminary bud-
get impact model (BIM) has been created to analyse the impact of introducing
fampridine to treat MS patients with walking impairment in the UK market.
METHODS: The BIM calculates the budget impact from a UK payer perspective of
introducing fampridine in addition to usual care to an eligible MS patient popula-
tion suffering from ambulation problems with an Expended Disability Severity
Scale (EDSS) between 4 and 7.5, using a 3 year time horizon and a market forecast.
The model conservatively assumes that all patients respond to treatment and
there is no effect of fampridine on usual care resource use. A monthly withdrawal
rate is also applied. RESULTS: The acquisition cost of fampridine is estimated at
£3800 per patient per year. An approximate eligible population of 35,000 MS pa-
tients is estimated from literature. The market forecast estimates an uptake of 3%,
10% and 16% of the eligible population in the first three years respectively, and the
estimated withdrawal rate is 2.2%. Compared to usual care alone, the annual re-
sults for the first three years show an additional budget of £3.4million, £10.9million
and £18.2million respectively. CONCLUSIONS: The model presents conservative
estimates whilst still showing a relatively low impact on the payer’s budget, dem-
onstrating that a major unmet need of MS patients can be met without a large
increase in budget. Further research is required into response rates, effect of fam-
pridine on usual care treatment costs to get a more accurate estimate of the impact
fampridine.
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OBJECTIVES: To assess the budget impact of the treatment for Relapsing Remitting
Multiple Sclerosis (RRMS), interferons, and glatiramer acetate, from the National
Health System (NHS) perspective.METHODS:A budget impact model was designed
to compare the cost of RRMS treatment in different settings, using a 5 year time-
horizon, considering different percentages of administration of each medication. A
reference setting o base case using all the available first line treatments (interfer-
ons and glatiramer acetate) was compared with 5 alternatives scenarios excluding
each one of these treatments. The cost analysis (2010 euros) includes direct med-
ical resources (drugs, administration, visits, disease management, diagnostic
tests). Unitary cost data was obtained from the health costs database e-Salud and
drugs Catalogue. RESULTS: Considering a cohort of 22,255 patients with RRMS, the
mean global budget impact per year would be € 260.775.470 in the base case. The
setting that excluded glatiramer acetate increases the budget impact in a 3.23% (€
372 per patient per year). Pharmacological costs were the key drivers of total cost
(90%). CONCLUSIONS: The use of glatiramer acetate in the first-line-treatment of
RRMS patients is a cost-saving strategy, which may decrease the budget impact
from the NHS perspective in Spain.
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OBJECTIVES: To estimate costs of managing corticosteroid (CS)-related adverse
events (AEs) within a systemic lupus erythematosus (SLE) population.METHODS:A
retrospective claims analysis (January 1, 2000–June 30, 2010) was conducted within
an SLE population to evaluate the risk of known CS-related chronic and acute AEs
among CS users and non-users by utilizing Cox proportional hazards models ad-
justing for patient characteristics, SLE severity, other SLE treatments, and AE-re-
lated risk factors. Associated costs were computed for AEs where the risk was
significantly different among CS users compared to non-users. CS users having a
chronic AE were followed for 12 months post-AE date to capture total costs, which
were compared to total costs of CS users who did not have a chronic AE during the
same time period. Predicted annual costs were generated using generalized linear
models controlling for baseline characteristics. The incremental difference in an-
nual costs among the two groups was considered attributable to the AE. For pa-
tients having an acute AE, disease-specific costs were calculated over a 12-month
timeframe post-AE date. RESULTS: SLE patients receiving CS were more likely to
develop chronic AEs (ie, cataracts, sleep disturbances, hypertension, type II diabe-
tes, migraine) and acute AEs (ie, pneumonia, herpes zoster, fungal infections, nau-
sea/vomiting). The average annual cost for managing AEs was highest for type II
diabetes ($9763), followed by hypertension ($8774), sleep disturbances ($5599), mi-
graine ($3591), cataracts ($2407), herpes zoster ($2079), pneumonia ($1726), nausea/
vomiting ($1357), and fungal infections ($857). When applying base rates and in-
creased risk estimates of each AE to the cost estimates, it costs an additional
$784/year per CS user to manage known CS-related AEs compared to CS non-users.
CONCLUSIONS: Within an SLE population, CS treatment is associated with addi-
tional costs of $784/year due to management of CS-related AEs. Providers and
payers should consider these potential costs of CS when making treatment deci-
sions.
PND13
MANAGEMENT OF FOCAL EPILEPSY TREATED BY POLYTHERAPY IN FRANCE:
THE COST OF PHARMACO-RESISTANCE
de Zélicourt M1, Laurendeau C1, Levy-Bachelot L2, Branchoux S2, Murat C2,
Vespignani H3, de Toffol B4, Fagnani F1
1Cemka, Bourg la Reine, France, 2Laboratoire GlaxoSmithKline, Marly le Roi, France, 3Centre
Hospitalier et Universitaire de Nancy, Nancy, France, 4CHU Bretonneau, Tours Cedex, France
OBJECTIVES: Approximately 50% of patients do not achieve seizure control with a
single antiepileptic drug (AED). With the advent of multiple AEDs in the past 15
years, the choice of optimal polytherapy remains difficult in absence of clinical
studies about the effectiveness of various combination therapies. This study aimed
at describing the current management of focal epilepsy treated by polytherapy in
France and at estimating the extra-costs of pharmacoresistance (PR) as redefined in
2009 by the International League Against Epilepsy (ILAE). METHODS: ESPERA is a
European multicenter, observational, cross-sectional study conducted in France
and Spain in 2010. A random sample of neurologists enrolled prospectively a sam-
ple of adult patients treated with at least two antiepileptic drugs (AEDs) in combi-
nation for focal epilepsy. The investigators classified their patients according to the
new ILAE criteria and this classification was then reviewed by two independent
experts. All items of medical resources use associated with epilepsy were collected
retrospectively over the last year and valued according to a societal perspective.
RESULTS: Seventy-one French neurologists collected analysable data on 405 pa-
tients. After review by experts, patients were finally classified as PR in 286 (70.6%) of
them, in 91 (22.4%) as responsive and in 28 (7%) as undefined. The mean annual
epilepsy related direct costs par patient were 4238 € (SD: 3772) in PR patients as
compared with 1907€ (SD: 1,739) in responsive patients. AEDs costs were estimated
2602€ and 1544€ respectively and PR patients were significantly more often hospi-
talized (mean annual cost: 1023€ versus 78€) and had more procedures (mean an-
nual cost: 194€ versus 53€). CONCLUSIONS: Despite the number of therapeutic
alternatives available in epileptic patients, a large proportion of them remain with
uncontrolled seizures yielding to significant extra costs.
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OBJECTIVES: To compare the expected costs (EC) of three different screening strat-
egies for cystic fibrosis implemented in Spain: TIR/DNA/DGGE, TIR/TIR/DNA, and
TIR/DNA. These strategies correspond to screening programs in Basque Country,
Castilla León and Canary Islands. METHODS: For each strategy, EC per child
screened, also EC per infant with CF and EC disaggregated by type of test was
estimated. In addition, sensitivity of each strategy was calculated. Unless there are
differences between unit cost along communities, the same unit cost source for all
programs was used, in order to allow comparisons. RESULTS: The estimated EC per
screened neonate were € 3.67, € 4.07, € 4.11 for TIR/ADN, TIR/ADN/DGGE, and TIR/
TIR/ADN respectively, showing that TIR/ADN/DGGE is the strategy with lowest EC
for its population. Regarding the sensitivity of the three strategies, the results
showed similar and high values for all of them, being the strategy of Basque Coun-
try which had highest value (99.37%). The ECs per neonate suffering CF were
82.703,48 €, 18.726,29 €, 16.604,10 € for TIR/ADN, TIR/ADN/DGGE, and TIR/TIR/ADN
respectively, showing highest cost per neonate with the disease, however the
power of this results is still low, and there are differences between incidences along
strategies. CONCLUSIONS: In this cost comparative study it was obtained that the
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most expensive screening program in term of population ECs is TIR/TIR/ADN. How-
ever, this strategy has the lowest EC/neonate with CF. In the opposite TIR/ADN has
the lowest EC in term of population but the highest cost in term of neonates with
CF. However more data are needed in order to increase the power of estimations. It
is clear that the factors which have most influences in cost difference between
regions are algorithm type used, order of diagnostic tests and cutoff points.
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OBJECTIVES: Migraine is associated with significant medical costs in Western
countries. However, there is currently limited information comparing the eco-
nomic burden of different types of migraine including chronic migraine (CM) (15
headache days/month), especially in Asia. This study aims to estimate the medical
costs associated with chronic migraine in Taiwan. METHODS: A retrospective
matched cohort study was conducted utilizing data from the Taiwan National
Health Insurance Research Database. Cases of chronic migraine were defined as
patients with  one neurological outpatient visit with primary or secondary ICD-
9-CM code of 346.11, diagnosed by neurologists in medical centers during 2007-
2008. The 1st comparison group was other migraine sufferers (346.XX), without any
migraine diagnosis before 2007, matched with cases at a 4:1 ratio by age, gender,
and hospital setting. The 2nd comparison group was the general population with-
out any migraine diagnosis during 2005-2009, matched with cases at a 4:1 ratio by
age, gender, urbanization level of the residence and income. Medical costs within
365 days after the index date were assessed using a two-part model: a logistic
regression to predict the probability of use of services and a generalized linear
model to predict utilization for users of services. RESULTS:A total of 723 and 727 of
CM patients were matched with 2384 of other migraine sufferers and 2906 of the
general population, respectively. Patient with CM had significantly higher total
medical costs versus those with other migraine (NT$52527 vs. NT$41886,
differenceNT$10641; p0.001) or the general population (NT$61018 vs. NT$21377,
differenceNT$39641; p0.001). The mean drug costs for CM sufferers were higher
than those with other migraine (NT$16617 vs. NT$11217, differenceNT$5400;
p0.001) or the general population (NT$19691 vs. NT$7105, differenceNT$12586;
p0.001). CONCLUSIONS: Consistent with a higher burden of illness, CM sufferers
in Taiwan had significantly higher medical costs than those with other migraine
diagnoses or the general population.
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OBJECTIVES: The information on Sclerosis Multiplex (MS) health care and social
expenditures is not publicly available in Slovakia. The objective of the Cost of
Illness study was to establish the current cost of MS in order to provide a basis upon
which the economic impact of new treatments can be estimated. METHODS: The
analysis was performed based on the several data sources. Information on health-
care and social expenditure were obtained from State Health and Social Insurance
Funds. As not all detailed data on expenditures were available in a necessary struc-
ture, the missing data were collected in the patient research. Both direct and indi-
rect costs were evaluated and dissagregated by the cost type and severity of the
disease based on the EDSS score. Capital method is the most common method
applied for calculation of Indirect costs in MS and it was used in order to get
comparison with the data published in other countries. RESULTS: In Slovakia, the
prevalence of MS is 112/100 thousands inhabitans. Total yearly MS expenditures in
2010 were 40,7 mill. EUR. Direct costs counted for 57% of total costs and the most of
them (95%) were caused by drugs, hospitalisations and diagnostics (mostly MRI)
expenditures. The highest share of Indirect costs represented Loss of productivity
(58%), followed by Disability pensions (37%) and Sick leave wage compensation
(4%). Direct and indirect costs per one patient represent 3770 Eur and 2896 Eur
respectively.CONCLUSIONS:The evidence of cost-effectiveness of new treatments
must be demonstrated in order to get reimbursement in Slovakia. According the
Slovak Guidelines only direct costs are accepted in cost-effectiveness submissions
and indirect costs are taken into account only in reasonable cases. Indirect costs
represent nearly half of total MS costs (43%) and therefore should be considered in
assessing the cost effectiveness of new comming innovative MS therapies.
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OBJECTIVES: A Multiple Sclerosis (MS) relapse refers to an episode of neurological
disturbance during which an acute worsening of function occurs, usually lasting
for several days or weeks. The TRIBUNE study provides a detailed exploration of
costs and quality of life (QoL) associated with MS relapses. METHODS: Patients in
five European countries (France, Germany, Italy, Spain, and UK) completed a self-
administered web-based questionnaire capturing information on demographics,
disease characteristics and severity (EDSS), co-morbidities, relapses, resource con-
sumption, and relevant aspects of QoL. The effect of relapses on the socioeconomic
burden was assessed by the difference in costs and QoL incurred by relapsing-
remitting MS (RRMS) patients with and without relapse(s) with EDSS score 5.
RESULTS: Out of 1261 patients that completed the questionnaire, 68% had RRMS
and 87% reported receiving MS treatment. Nearly half (48%) of the RRMS patients
with an EDSS score  5 reported having at least one relapse during the past year.
This sub-group reported a higher consumption of direct medical resources, profes-
sional and informal care, and more sick-leave days compared to patients without
relapse(s). The difference in costs of patients with relapse(s) compared to those
without ranged between €3,321 and €9,430 across countries. Relapses requiring
treatment with steroids or hospitalization resulted in higher costs compared with
relapses not needing an intervention; €4,062 - €10,589 versus €340 - €5,096 respec-
tively across countries. QoL outcomes were also correlated with relapse(s).
CONCLUSIONS: The additional burden imposed by relapses is important both in
terms of excess cost and the impact on quality of life. The use of effective treat-
ments that reduce the frequency of relapses, in addition to providing clinical ben-
efits, could potentially lessen the clinical and socioeconomic burden of MS.
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OBJECTIVES: Muscular dystrophies (MD) are a group of genetically heterogeneous
disorders, characterized by progressive muscle wasting and weakness. The MDs
vary in incidence, pattern of inheritance, age of onset (though frequently among
pediatrics), muscles affected, and progression. Overall, MD imposes a significant
economic burden on both patients and society in general. This study assessed
recent trends in pediatric MD hospitalizations in the United States (US).METHODS:
Data for pediatric (20 years) hospitalizations with a primary diagnosis of MD
(ICD-9-CM codes 359.0, 359.1, or 359.2) from the 1997, 2000, 2003, and 2006 HCUP
Kids’ Inpatient Databases, nationally representative databases of pediatric hospi-
talizations in the US, were analyzed. Weighted estimates of the number of hospi-
talizations for MD, characteristics of these hospitalizations (e.g., patient demo-
graphics), and associated resource-based measures (i.e., charges, length of stay
[LOS], and most common primary procedures performed) were derived. RESULTS:
Between 1997 and 2006, the rate of pediatric MD-related hospitalizations (per
100,000 2010 US pediatric population) has increased, from 3.57/100,000 in 1997 to
4.12/100,000 in 2000, 4.39/100,000 in 2003, and 4.56/100,000 in 2006. Mean LOS de-
creased appreciably between 1997 and 2000, then remained unchanged through
2006 (10.7 days in 1997, and 9.4 days in 2000, 2003, and 2006). During each year of the
study period, continuous mechanical ventilation and dorsal and dorsolumbar fu-
sion (posterior technique) were the most frequently observed primary procedures.
Finally, mean total charges (2010 US $) for MD-related stays increased roughly 21%,
from $53,739 (1997) to $65,280 (2006). CONCLUSIONS: We examined rates of pedi-
atric MD-related hospitalizations in the US, and observed an increase in the rate of
hospitalizations over time. LOS decreased from 1997 to 2000, then remained con-
stant through 2006, although total charges increased significantly over this time.
These findings provide insight into MD-related hospitalizations in the US and high-
light the need to further examine the burden of MD.
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OBJECTIVES: Multiple sclerosis (MS) is a prevalent, chronic and disabling disease,
affecting mainly young adults. The most common clinical form presents with re-
current episodes of focal neurological deficits, called relapses. The aim of this work
is to analyse the socioeconomic cost of an MS relapse. METHODS: A prospective
observational study performed in 2 MS Units, located in Barcelona (Spain). We
included 100 consecutive patients (april 2007 to november 2009) who have had a
relapse. Patients were invited to answer a questionnaire after the relapse, with
demographic, social, employment status data and clinical aspects, as well as data
about the consumption of sanitary and no-sanitary resources during the relapse.
The unit costs were calculated according to the Catalan Health Service. RESULTS:
The mean age was 38.3 years, and 2 out of 3 were female sex. The mean duration of
disease was 9.5 years. 94% of patients had recurrent-remitting MS and secondary-
progressive 6%. At the time of the relapse 76% had a mild disability, 22% modeate
and 2% severe. 63% of patients reported to be employed. The relapse required a
mean of 3.1 medical visits, 3.7 days of outpatient hospitalization, 22.5 hours for
informal care and 12.4 sick leave days. The MS relapse costs resulted 2.609 euros
per patient. This included 1.524 euros of direct costs (medical visits: 183,7 euros,
complementary tests: 28,5 euros, hospitalizations days: 32,5 euros, outpatient hos-
pitalization:777,8 euros, displacements:152,9 euros, rehabilitation: 98,9 euros, in-
formale care: 151,7 euros, formal care: 21,5 euros and treatment: 76,5 euros) and
1.085 euros of indirect costs (sick leave days). CONCLUSIONS: Total cost of MS
relapse resulted (included direct and indirect costs) 2.609 euros per patient. The
main contributors to total cost were sick leaves and outpatient hospitalization.
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